• Home
  • Ketamine-Assisted Psychotherapy: Science, Theory, and Practice

Ketamine-Assisted Psychotherapy: Science, Theory, and Practice

  • 10 Dec 2021
  • 6:00 PM - 7:30 PM
  • Zoom

Registration


Register

You are invited to the following event:

 

SBCPA Evening Salon

Friday, December 10, 2021

6:00 pm – 7:30 pm


Ketamine - Assisted Psychotherapy: Science, Theory, and Practice

with Dr. Cole Marta and Ashley Booth, AWS, MS



Presenters:


COLE J. MARTA, MD completed undergraduate studies at UC Santa Cruz in molecular, cellular, and developmental biology and earned an MD from Chicago Medical School. He was a Junior Specialist in a Howard Hughes Medical Institute laboratory studying neurogenetics. He completed his residency at the UCLA VA training program where he participated in cutting-edge research related to mood, anxiety, substance use, and post-traumatic stress disorder. He published papers in academic journals, and has presented at conferences on the safety and efficacy of psychedelics in the context of both healing intent and abuse populations. Since graduating from psychiatric training, he has founded a research company and served as Principal Investigator on phase II and phase III trials for MDMA-assisted Psychotherapy for PTSD the results of which have been published in Nature Medicine. Dr. Marta also has experience and interest in harm reduction efforts, and public speaking on those topics. Currently,  he is the co-founder and medical director of the California Center for Psychedelic Therapy in Hollywood, CA. www.psychedelictherapyca.com 


ASHLEY BOOTH, ASW, MS offers Ketamine-Assisted Psychotherapy, somatic and mindfulness-based psychotherapy, psychedelic integration and Internal Family Systems therapy as a co-founder and clinician at the California Center for Psychedelic Therapy. She left a career in environmental research in 2016 to pursue her passion for psychedelic education, advocacy, and therapy. Ashley brings a wealth of knowledge as the founder of the Southern California psychedelic society, the Aware Project: Rethinking Psychedelics, and as a psychedelic integration coach and co-founder of InnerSpace Integration. She is also a co-therapist on the Los Angeles Phase III team for the MAPS-sponsored clinical trial of MDMA-assisted psychotherapy for the treatment of PTSD.


Course Outline

 

Timeline:

5:45- 6:00pm          Greet, sign in, and socialize

6:00- 6:05pm          Introduction of speaker and opening remarks

6:05-6:10pm           Overview of the history of psychedelics

6:10-6:20pm           Explain differences in psychedelic use contexts and how they may affect outcomes

6:20-6:35pm           Summarize data from clinical studies of ketamine research

6:35-6:50pm           Describe the clinical pharmacology of ketamine

6:50-7:00pm             Describe protocols and theory behind psychedelic therapy & healing

7:00-7:15pm               Present clinical vignettes

7:15-7:30pm               Q&A/evaluations


Topic:

With the rapidly growing interest in psychedelic-assisted psychotherapy modalities, ketamine is the only available clinical option currently. The salon presentation offers a review of the historical and clinical context of psychedelics and the current research supporting the safety and effectiveness of ketamine-assisted psychotherapy for the treatment of various indications. The clinical pharmacology of ketamine for off-label applications in treatment of depression, PTSD, anxiety, and OCD will be discussed. Case vignettes will be used to demonstrate service provision, theory of approach, and effectiveness in different populations.


Learning Objectives:

 At the end of the presentation, attendees will be able to:

1)     Describe the similarities and differences between the use of ketamine and other psychedelics within the context of psychotherapy

2)     Assess when ketamine-assisted psychotherapy may be clinically appropriate

3)     After attending this webinar, participants will be able to explain service provision theory and harm reduction considerations. 


References

Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33 (2) 


Ryan WC, Marta CJ, Koek RJ. (2014). Ketamine and Depression: A Review. International Journal of Transpersonal Studies, 33(2), 40-74.  


Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N.  &  Wolfson, P. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs, 51(2), 189-198.


Continuing Education:

CPA is co-sponsoring with Santa Barbara County Psychological Association (SBCPA). The California Psychological Association is approved by the American Psychological Association to sponsor continuing education for psychologists. CPA maintains responsibility for this program and its contents.

 

Important Notice:

Those who attend the workshop and complete the CPA evaluation form will receive (1.5) continuing education credits. Please note that APA CE rules require that we give credit only to those who attend the entire workshop. Those arriving more than 15 minutes after the start time or leaving before the workshop is completed will not receive CE credits.


Please Note: This salon will be held via zoom. 




© 2012 SBCPA. Designed by POP
Powered by Wild Apricot Membership Software